Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 5 clinical trials
Camrelizumab Combined With Apatinib Mesylate for Head and Neck Squamous Cell Carcinoma

This is a prospective, open-labelled study to evaluate the efficacy and safety of camrelizumab combined with apatinib mesylate in the induction treatment of patients with locally advanced head and neck squamous cell carcinoma who were judged surgically unresectable or appropriate for non-surgical definitive therapy.

cancer
head and neck cancer
measurable disease
apatinib
advanced head and neck squamous cell carcinoma
  • 0 views
  • 19 Feb, 2024
  • 1 location
Neoadjuvant PD-1 Antibody Plus Apatinib or Chemotherapy for Non-small Cell Lung Cancer

The participants will receive neoadjuvant PD-1 inhibitor (camrelizumab) combined with antiangiogenic drug (apatinib) or platinum-based chemotherapy.

pd-1 inhibitor
angiogenesis inhibitor
kidney function test
platinum-based chemotherapy
camrelizumab
  • 0 views
  • 19 Feb, 2024
  • 1 location
Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL

This study will evaluate the efficacy and safety of camrelizumab in combination with apatinib in in patients with relapsed or refractory diffuse large B cell lymphoma failed from second line chemotherapy.

g-csf
creatinine clearance rate
anticoagulant therapy
diffuse large b-cell lymphoma
pulse oximetry
  • 0 views
  • 19 Feb, 2024
  • 1 location
Inductive Camrelizumab and Apatinib for Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma

The innovation of this study is the combination of immune checkpoint inhibitor, Camrelizumab, and targeted drug against VEGFR, Apatinib, as an inductive therapy to treat the patients with locally advanced OSCC, followed with radical surgery and post-operative radiotherapy/chemoradiotherapy, the major pathologic response and safety will be evaluated as the primary …

cancer
vascular endothelial growth factor receptor 2
vascular endothelial growth factor
white blood cell count
vegf
  • 0 views
  • 19 Feb, 2024
  • 1 location
Prediction of Therapeutic Response of Apatinib in Recurrent Gliomas

This study aims to collect clinical, radiological and histopathology imaging including detailed radiological data, survival data, clinical parameters, molecular pathology and images of HE slices in patients with recurrent gliomas whose are treated with Apatinib, for evaluating the efficacy and safety of Apatinib. Moreover, by leveraging artificial intelligence, this study …

vascular endothelial growth factor receptor 2
postoperative complication
vascular endothelial growth factor
liver metastasis
platelet count
  • 0 views
  • 19 Feb, 2024
  • 1 location